Search results
Author(s):
Erik M Kelly
,
Donald E Cutlip
Added:
3 years ago
Diabetes mellitus is one of the most common chronic diseases, affecting >30 million people in the US and 422 million worldwide.1,2 Alarmingly, both the incidence and prevalence of type 2 diabetes have doubled in the US since 1990.3 This is driven by an aging population, obesity, physical inactivity, and prolonged survival in those with diabetes, among other factors. It is estimated that…
View more
Eugene Braunwald
Research Area(s) / Expertise:
Job title: Distinguished Hersey Professor of Medicine, MACC
Author
Author(s):
Neal M Dixit
,
Shivani Shah
,
Boback Ziaeian
,
et al
Added:
2 years ago
Author(s):
Stephen Ku
,
Steven V Edelman
Added:
3 years ago
Cardiovascular disease is an important cause of morbidity and mortality in patients with type 1 and especially type 2 diabetes mellitus.1,2 Data from prospective studies suggest that diabetes is associated with a two to fourfold excess risk of coronary heart disease and coronary death.3–5 It was therefore hoped that controlling hyperglycemia would reduce cardiovascular disease incidence and…
View more
Author(s):
Ariana Traub
,
Apoorva Sharma
,
Maria Carolina Gongora
Added:
2 months ago
Author(s):
Aishat F Mustapha
,
Anna M Goebel
,
Bryan J Wells
Added:
6 months ago
Author(s):
Mikhail Kosiborod
Added:
6 years ago
Mikhail Kosiborod discusses the CVD-REAL 2 study - Lower Risk of Cardiovascular Events and Death Associated With Initiation of SGLT-2 Inhibitors Versus Other Glucose Lowering Drugs.
Filmed on-site at the American College of Cardiology congress 2018 in Orlando, USA.
View more
Author(s):
Muthiah Vaduganathan
Added:
3 years ago
In this video, Dr Muthiah Vaduganathan (Brigham and Women's Hospital, Boston, US) shares the findings from the EMPA-REG OUTCOME trial. The goal of the trial was to assess the cardiovascular (CV) safety of empagliflozin, a sodium–glucose cotransporter 2 (SGLT-2) inhibitor, in patients with type 2 diabetes mellitus (T2DM) at high risk for CV events.
Questions:
1. What is the background of…
View more
Felipe Martínez
Research Area(s) / Expertise:
Author
Author(s):
Carrie Eshelbrenner
,
Karina Vasquez
,
Liberty O Yanze
,
et al
Added:
3 years ago
Cardiologists in general are strong advocates of evidence-based medicine, due to the critical nature of ischemic heart disease in patients. The use of up-to-date scientific evidence from research is paramount as the basis for making many medical decisions. There are three major advantages to using this approach. First, it offers some of the most objective ways to determine and maintain consistent…
View more